| Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial A Mangia, N Minerva, D Bacca, R Cozzolongo, GL Ricci, V Carretta, ... Hepatology 47 (1), 43-50, 2008 | 321 | 2008 |
| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ... The Lancet 391 (10138), 2417-2429, 2018 | 188 | 2018 |
| Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B P Lampertico, M Viganò, GG Di Costanzo, E Sagnelli, M Fasano, ... Gut 62 (2), 290-298, 2013 | 132 | 2013 |
| Changing pattern of chronic hepatitis D in Southern Europe F Rosina, P Conoscitore, R Cuppone, G Rocca, A Giuliani, R Cozzolongo, ... Gastroenterology 117 (1), 161-166, 1999 | 127 | 1999 |
| Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection L Caradonna, ML Mastronardi, T Magrone, R Cozzolongo, R Cuppone, ... Current pharmaceutical design 8 (11), 995-1005, 2002 | 105 | 2002 |
| Ribavirin treatment for chronic hepatitis D: a pilot study A Garripoli, V Di Marco, R Cozzolongo, C Costa, A Smedile, A Fabiano, ... Liver 14 (3), 154-157, 1994 | 87 | 1994 |
| Epidemiology of HCV infection in the general population: a survey in a southern Italian town R Cozzolongo, AR Osella, S Elba, J Petruzzi, G Buongiorno, V Giannuzzi, ... Official journal of the American College of Gastroenterology| ACG 104 (11 …, 2009 | 81 | 2009 |
| Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype … A Mangia, N Minerva, D Bacca, R Cozzolongo, E Agostinacchio, F Sogari, ... Hepatology 49 (2), 358-363, 2009 | 81 | 2009 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver International 37 (4), 514-528, 2017 | 74 | 2017 |
| Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C PA Maiellaro, R Cozzolongo, P Marino Current pharmaceutical design 10 (17), 2101-2109, 2004 | 42 | 2004 |
| Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/Ribavirin L Amati, L Caradonna, T Magrone, ML Mastronardi, R Cuppone, ... Current pharmaceutical design 8 (11), 981-993, 2002 | 41 | 2002 |
| Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin A Andriulli, V Di Marco, M Margaglione, AM Ippolito, G Fattovich, ... Journal of Hepatology 60 (1), 16-21, 2014 | 40 | 2014 |
| Onset of type 1 diabetes mellitus during peginterferon α-2b plus ribavirin treatment for chronic hepatitis C R Cozzolongo, C Betterle, P Fabris, MP Albergoni, E Lanzilotta, ... European journal of gastroenterology & hepatology 18 (6), 689-692, 2006 | 37 | 2006 |
| Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection E Jirillo, B Greco, L Caradonna, R Satalino, V Pugliese, R Cozzolongo, ... Immunopharmacology and immunotoxicology 17 (2), 347-364, 1995 | 35 | 1995 |
| Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α E Jirillo, L Amati, L Caradonna, B Greco, R Cozzolongo, R Cuppone, ... Immunopharmacology and immunotoxicology 20 (1), 1-14, 1998 | 32 | 1998 |
| Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin A Mangia, O Dalgard, N Minerva, H Verbaan, D Bacca, H Ring‐Larsen, ... Alimentary pharmacology & therapeutics 31 (12), 1346-1353, 2010 | 31 | 2010 |
| Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens? VC Di Maio, V Cento, M Aragri, S Paolucci, T Pollicino, N Coppola, ... Journal of hepatology 68 (3), 597-600, 2018 | 29 | 2018 |
| Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon R Cozzolongo, R Cuppone, V Giannuzzi, L Amati, L Caradonna, ... Alimentary pharmacology & therapeutics 15 (1), 129-135, 2001 | 25 | 2001 |
| Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study M Persico, A Aglitti, M Milella, C Coppola, V Messina, E Claar, I Gentile, ... Liver International 39 (10), 1852-1859, 2019 | 21 | 2019 |
| Aerobic physical activity and a low glycemic diet reduce the AA/EPA ratio in red blood cell membranes of patients with NAFLD V Tutino, V De Nunzio, MG Caruso, C Bonfiglio, I Franco, A Mirizzi, ... Nutrients 10 (9), 1299, 2018 | 18 | 2018 |
Angelo AndriulliCasa Sollievo SofferenzaEmail verificata su operapadrepio.it
